JAMA Medical News

Dr. Robert Gabbay, an endocrinologist and chief scientific officer at the ADA, shares insights on groundbreaking diabetes research. He discusses impressive advancements in weight loss medications and the innovation of GLP-1 receptor agonists for kidney health and diabetes prevention. The talk highlights the new potential for inhaled insulin and the importance of continuous glucose monitoring technology. Dr. Gabbay also emphasizes the need for combining medication with lifestyle changes, all amidst exciting collaborations between academia and startups.

This is a 2-part Q&A series with the US Surgeon General. In part 1, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, interviews Vivek H. Murthy, MD, MBA, to discuss the issue of gun violence as a pressing public health crisis and the critical role of public health leadership in combating this issue. Related Content: US Surgeon General Vivek Murthy: Firearm Violence Is a Public Health Crisis Q&A With Surgeon General Vivek H. Murthy, MD, MBA: Gun Violence Is a Public Health Crisis

Nora Disis, MD, editor in chief of JAMA Oncology and a JAMA deputy editor, and guests share JAMA Network highlights from the American Society of Clinical Oncology’s annual meeting, including new research on colorectal cancer screening, an antibody therapy for non–small cell lung cancer, access to oncology clinical trials, and a new model of palliative care for patients with cancer. Related Content: Refining Colon Cancer Screening, Antibody Therapy for Lung Cancer, and More—Highlights From ASCO 2024

Sachin Kheterpal discusses the potential of wearable devices in healthcare, emphasizing data integration and AI for better patient care. The role of modern sensors and wearables in behavior change is explored, along with the challenges of implementing predictive models in healthcare. The chapter also delves into the evolving landscape of healthcare technology and the importance of maximizing benefits while addressing barriers.

Topics discussed in the podcast include the resurgence of syphilis in the US due to various factors, the potential shift in statin eligibility with a new CVD risk calculator, challenges in syphilis prophylaxis with doxycycline, alarming increase in congenital syphilis cases, updated recommendations for screening in pregnancy, and the introduction of the PREVENT calculator for personalized statin recommendations based on health factors and social deprivation.

Daniel Gibbs, MD, received an Alzheimer disease diagnosis 8 years ago, and in hindsight, believes the earliest symptoms appeared years before that. In this podcast, the retired neurologist speaks with JAMA Medical News lead senior staff writer Rita Rubin, MA, about how even with the neurodegenerative condition, it’s still possible to enjoy a life well-lived. Related Content: Neurologist Faces His Alzheimer Diagnosis Determined to Lessen Stigma Surrounding the Disease A Neurologist Learned He Had Alzheimer Disease 8 Years Ago—Here’s What He Wants People to Know

College athlete suicides doubled over 20 years due to societal pressures. Bird flu outbreak in dairy cows raises public health concerns. Combined COVID-19 and flu vaccines could be available next year.

Saurabh Jha discusses AI in radiology with a focus on improving access to medical imaging in remote areas. They explore the evolution of AI in radiology, enhancing communication between radiologists and general practitioners, and the challenges faced by machines in replicating nuanced decision-making.

Can AI/machine learning-driven digital phenotyping facilitate global personalized medicine? In this Q&A, Vikram Patel, MBBS, PhD, the Paul Farmer Professor and chair of the Department of Global Health and Social Medicine at Harvard Medical School, joins JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, to discuss how AI can enhance assessment and treatment solutions across lower-income nations. Related Content: One Day, AI Could Mean Better Mental Health for All

An Explosion of Food Is Medicine Research Could Change Health Care; Blockbuster Obesity Drugs Have Potential New Uses Related Content: Could GLP-1 Receptor Agonists Like Semaglutide Treat Addiction, Alzheimer Disease, and Other Conditions? Produce Prescriptions Sound Good, but Data to Support Them Are Lacking—That Could Soon Change